|
Phase 2 Study of VELCADE in Subjects with Relapsed or Refractory Mantle Cell Lymphoma Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Phase 2 Study of VELCADE in Subjects with Relapsed or Refractory Mantle Cell Lymphoma conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Phase 2 Study of VELCADE in Subjects with Relapsed or Refractory Mantle Cell Lymphoma Clinical research trials and Phase 2 Study of VELCADE in Subjects with Relapsed or Refractory Mantle Cell Lymphoma health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Phase 2 Study of VELCADE in Subjects with Relapsed or Refractory Mantle Cell Lymphoma. Phase 2 Study of VELCADE in Subjects with Relapsed or Refractory Mantle Cell Lymphoma Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Phase 2 Study of VELCADE in Subjects with Relapsed or Refractory Mantle Cell Lymphoma clinical trial. Test subjects typically receive the most expert healthcare available for their Phase 2 Study of VELCADE in Subjects with Relapsed or Refractory Mantle Cell Lymphoma condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase 2 Study of VELCADE in Subjects with Relapsed or Refractory Mantle Cell Lymphoma  Phase 2 Study of VELCADE in Subjects with Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 Study of VELCADE in Subjects with Relapsed or Refractory Mantle Cell Lymphoma
For Condition: Mantle Cell Lymphoma
Status: Recruiting
Sponsor(s): Millennium Pharmaceuticals ,
Synopsis: The purpose of this study is to find out whether treatment with VELCADE will increase the time it takes for lymphoma to get worse.
Details: VELCADE is approved in multiple myeloma for patients who have received two prior therapies and their disease came back or got worse while on their second therapy. VELCADE is currently being studied in other types of cancers.
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria - 18 years of age or older - Confirmed diagnosis of mantle cell lymphoma - Documented relapse or progressive disease following 1 or 2 prior lines of anti-cancer therapy. At least one of those regimens must have included an anthracycline or mitoxantrone. Relapsed or progressive disease, since last therapy must be documented by new lesions or objective evidence of the progression of existing lesions. - At least 1 measurable or evaluable site of disease - Voluntary consent Exclusion Criteria - Previous treatment with VELCADE - Any experimental or anti-cancer therapy within 3 weeks before the first dose of study drug - Radiation therapy within 3 weeks before the first dose of study drug - Major surgery with 2 weeks before the first dose of study drug - Rituximab, Campath, or other unconjucated therapeutic antibody within 4 weeks before the first dose of study drug - Radioimmunotherapy or other toxin immunoconjugates such as Zevalin or Bexxar within 10 weeks before the first dose of study drug - History of allergic reactions to boron or mannitol compounds - Diagnosed or treated for another malignancy other than mantle cell lymphoma with 5 years before the first dose of study drug - Active systemic infection requiring treatment - Women patients must not be pregnant or breast-feeding, confirmed through pregnancy test obtained during screening (this test is not required for women who are post-menopausal or surgically sterile) - Serious medical or psychiatric illness likely to interfere with participation in this clinical study - Concurrent treatment with another investigational drug or participation in non-treatment studies is not allowed if it interferes with participation in this clinical study
Total Enrollment: 152
Location and Contact Information:
Onc/Hem Associates of Kansas City *Recruiting*
Kansas City, Missouri, 64111
United States
Recruiting Robert Belt
University of Nebraska Medical Center *Not yet recruiting*
Omaha, Nebraska, 68198
United States
Not yet recruiting
Beth Israel Medical Center *Recruiting*
New York City, New York, 10003
United States
Recruiting Bruce Culliney
H. Lee Moffitt Cancer Center & Research Institute *Recruiting*
Tampa, Florida, 33612
United States
Recruiting Benjamine Djulbegovic
University of North Carolina *Recruiting*
Chapel Hill, North Carolina, 27599
United States
Recruiting Robert Orlowski
Sarah Cannon Cancer Center *Recruiting*
Nashville, Tennessee,
United States
Recruiting John Hainsworth
City of Hope Comprehensive Cancer Center *Recruiting*
Duarte, California, 91010-3000
United States
Recruiting Armita Krishnan
The Rush Cancer Center *Recruiting*
Chicago, Illinois, 60612
United States
Recruiting Stephanie Gregory
Alta Bates Medical Center *Recruiting*
Berkeley, California, 94704
United States
Recruiting David Irwin
Georgetown University Medical Center Lombardi Cancer Center *Recruiting*
Washington D.C., District of Columbia, 20007
United States
Recruiting Said Baidas
Indiana University Cancer Center *Recruiting*
Indianapolis, Indiana, 46202
United States
Recruiting Kristen Ganjoo
University of Alabama *Recruiting*
Birmingham, Alabama, 35294
United States
Recruiting Andres Forero
University of Colorado Cancer *Not yet recruiting*
Denver, Colorado, 80262
United States
Not yet recruiting
Oregon Health Science University *Recruiting*
Portland, Oregon, 97239
United States
Recruiting Elliot Epner
UCLA School of Medicine *Recruiting*
Los Angeles, California, 90095
United States
Recruiting Christos Emmanouildes
Dartmouth-Hitchcock Medical Center *Recruiting*
Lebanon, New Hampshire, 03756
United States
Recruiting Marc Gautier
Western Pennsylvania Hospital *Recruiting*
Pittsburgh, Pennsylvania, 15224
United States
Recruiting John Lister
Memorial Sloan Kettering Cancer Center *Not yet recruiting*
New York City, New York, 10021
United States
Not yet recruiting
Fox Chase Cancer Center *Recruiting*
Philadelphia, Pennsylvania, 19111
United States
Recruiting Russel Schilder
Loma Linda Cancer Research Institute *Recruiting*
Loma Linda, California, 92354
United States
Recruiting Jesus Berdeja
New York Hospital Cornell Medical Center *Recruiting*
New York City, New York, 10021
United States
Recruiting John Leonard
Cancer Care Associates *Recruiting*
Oklahoma City, Oklahoma, 73112
United States
Recruiting Romeo Mandanas
University Hospital-Madison Wisconsin *Recruiting*
Madison, Wisconsin, 53792
United States
Recruiting Brad Kahl
The Emory Clinic *Recruiting*
Atlanta, Georgia, 30322
United States
Recruiting Sagar Lonial
Stanford University *Recruiting*
Palo Alto, California, 94304
United States
Recruiting Sandra Horning
MD Anderson Cancer Center *Recruiting*
Houston, Texas, 77030
United States
Recruiting Andre Goy
Vanderbilt University *Recruiting*
Nashville, Tennessee, 37232
United States
Recruiting David Morgan
University of Pennsylvania Cancer Center *Recruiting*
Philadelphia, Pennsylvania, 19104
United States
Recruiting Edward Stadtmauer
Cancer Care Associates *Recruiting*
Tulsa, Oklahoma, 74136
United States
Recruiting Alan Keller
St Lukes-Roosevelt Hospital *Recruiting*
New York City, New York, 10019
United States
Recruiting Michael Grossbard
North Memorial Hospital *Recruiting*
Robbinsdale, Minnesota, 55422
United States
Recruiting Martin Oken
University of Rochester Medical Center *Recruiting*
Rochester, New York, 14642
United States
Recruiting Steven Bernstein
University of Chicago Medical Center *Recruiting*
Chicago, Illinois, 60637
United States
Recruiting Sonali Smith
University of Iowa Hospital Division *Recruiting*
Iowa City, Iowa, 52242
United States
Recruiting James Wooldridge
Wake Forest, University health Sciences/Comprehensive Cancer Center *Recruiting*
Winston Salem, North Carolina, 27157
United States
Recruiting David Hurd
Additional Information:
Study ID Numbers: M34103-053;
Study Start Date: June 2003
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00063713
Other Mantle Cell Lymphoma Studies:
1. Phase 2 Study of VELCADE in Subjects with Relapsed or Refractory Mantle Cell Lymphoma
2. Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma
3. RAD001 in Patients with Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia in Blastic-Phase, Agnogenic Myeloid Metaplasia, Chronic Lymphocytic Leukemia, T-Cell Leukemia, or Mantle Cell Lymphoma
4. Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
Related Studies:
Other Mantle Cell Lymphoma Clinical Trials
Other District of Columbia Clinical Trials
Other Washington D.C. Clinical Trials
Phase 2 Study of VELCADE in Subjects with Relapsed or Refractory Mantle Cell Lymphoma
|
|
|
|
|
|
|
|
